Evidence map›Paper›PMID 34576020›Full record

ArticleInternational journal of molecular sciences2021

Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma.

Ekaterina Blinova, Elena Samishina, Olga Deryabina, Dmitry Blinov, Dmitry Roshchin, Evgeniia Shich, Oxana Tumutolova, Ilya Fedoseykin, Anna Epishkina, Haydar Barakat and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ekaterina BlinovaDepartment of Clinical Anatomy and Operative Surgery, Department of Pharmacology and Pharmaceutic Technology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia.
Elena SamishinaLaboratory of Molecular Pharmacology and Drug Design, Department of Pharmaceutical Chemistry, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraja Kupavna, Russia.
Olga DeryabinaLaboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia.
Dmitry BlinovLaboratory of Molecular Pharmacology and Drug Design, Department of Pharmaceutical Chemistry, All-Union Research Center for Biological Active Compounds Safety, 23 Kirova Street, 142450 Staraja Kupavna, Russia.ORCID 0000-0002-8385-4356
Dmitry RoshchinDepartment of Oncological Urology, Russian National Research Medical Center of Radiology, Botkinsky Proezd, 125284 Moscow, Russia.
Evgeniia ShichDepartment of Clinical Anatomy and Operative Surgery, Department of Pharmacology and Pharmaceutic Technology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia.
Oxana TumutolovaLaboratory of Pharmacology, Department of Pathology, National Research Ogarev Mordovia State University, 68 Bolshevistskaya Street, 430005 Saransk, Russia.
Ilya FedoseykinDepartment of Clinical Anatomy and Operative Surgery, Department of Pharmacology and Pharmaceutic Technology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia.
Anna EpishkinaDepartment of Clinical Anatomy and Operative Surgery, Department of Pharmacology and Pharmaceutic Technology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia.
Haydar BarakatDepartment of Propaedeutic of Dental Diseases, People's Friendship University of Russia, 6 Miklukho-Maklaya Street, 117198 Moscow, Russia.ORCID 0000-0003-0911-3063
Andrey KaprinDepartment of Oncological Urology, Russian National Research Medical Center of Radiology, Botkinsky Proezd, 125284 Moscow, Russia.
Kirill ZhandarovDepartment of Clinical Anatomy and Operative Surgery, Department of Pharmacology and Pharmaceutic Technology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia.
Dmitrij PerepechinDepartment of Oncological Urology, Russian National Research Medical Center of Radiology, Botkinsky Proezd, 125284 Moscow, Russia.
Dmitrij MerinovDepartment of Oncological Urology, Russian National Research Medical Center of Radiology, Botkinsky Proezd, 125284 Moscow, Russia.
Gordey BrykinDepartment of Clinical Anatomy and Operative Surgery, Department of Pharmacology and Pharmaceutic Technology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia.
Karen ArutiunianDepartment of Urology, Andrology and Oncology, Pirogov Russian National Research Medical University, 1 Ostrovityanova Street, 117997 Moscow, Russia.
Stanislav SerebrianyiDepartment of Oncological Urology, Russian National Research Medical Center of Radiology, Botkinsky Proezd, 125284 Moscow, Russia.
Artem MirontsevDepartment of Clinical Anatomy and Operative Surgery, Department of Pharmacology and Pharmaceutic Technology, Sechenov University, 8/1 Trubetzkaya Street, 119991 Moscow, Russia.
Andrew KozdobaDepartment of Urology, Andrology and Oncology, Pirogov Russian National Research Medical University, 1 Ostrovityanova Street, 117997 Moscow, Russia.

Funding

Sechenov University internal grant 2020/15
6 · The paper itself

Abstract

backgroundThe possible involvement of p53 signaling, FGFR3 expression, and

methodstwenty lines of patient-derived xenografts (PDXs) of relapsed high-PD-L1(+) double-negative NMIBC were developed, of which 10 lines represented high-grade tumors and the other ones-low-grade bladder cancer. Acceptors of each grade-related branch received specific anti-PD-L1 antibodies. Animals' survival, tumor-doubling time, and remote metastasis were followed during the post-interventional period. PD-L1, GATA3, CR5/6, and p53 protein expressions in engrafted tumors were assessed by immunohistochemistry. The FGFR3 expression and

resultsThe expression of p53 protein is an independent factor affecting the animals' survival time [HR = 0.036,

conclusionsp53 expression may be considered as a prognostic factor for the anti-PD-L1 treatment efficacy of low-grade high-PD-L1-positive GATA3(-)/CR5/6(-)-relapsed noninvasive bladder cancer.

Indexed as

AgedAnimalsAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalCarcinomaFemaleHumansMaleMiceMice, SCIDMiddle AgedReceptor, Fibroblast Growth Factor, Type 3Tumor Suppressor Protein p53Urinary Bladder NeoplasmsXenograft Model Antitumor AssaysAntibodies, MonoclonalAntineoplastic Agents, ImmunologicaldurvalumabFGFR3 protein, humanReceptor, Fibroblast Growth Factor, Type 3Tumor Suppressor Protein p53anti-PD-L1 therapydouble-negative molecular subtypeFGFR3 expressionFGFR3 mutationshuman-derived xenograft modelmicenonmuscular invasive bladder cancerp53 expressionresponse

Identifiers

PMID34576020
PMCPMC8465184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.